CASP3 and diabetic cardiomyopathy: With the suppression of the inflammatory cascade, EMPA pretreatment successfully decreased the ovarian caspase-3 level, as consistent with other previous studies that concluded the ability of EMPA to reduce caspase-3 expression in rats with diabetic cardiomyopathy as caspase-3 is an important cell marker for the apoptotic signal pathway [36,37].